Patent application number | Description | Published |
20150150957 | Consensus Prostate Antigens, Nucleic Acid Molecule Encoding The Same And Vaccine And Uses Comprising The Same - Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided. | 06-04-2015 |
20150328298 | WT1 Vaccine - Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated WT1 antigen. Vectors, compositions and vaccines comprising one or more nucleic acid sequences that encode a mutated WT1 antigen are disclosed. Methods of treating an individual who has a WT1-expressing tumor and methods of preventing a WT1-expressing tumor are disclosed. Mutated WT1 antigen is disclosed. | 11-19-2015 |
20160022802 | Novel Vaccines Against Multiple Subtypes Of Dengue Virus - An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide, such as a consensus dengue prME that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all 4 dengue subtypes. | 01-28-2016 |
20160030536 | Cancer Vaccines And Methods Of Treatment Using The Same - Disclosed herein are compositions and methods for treating cancer and in particular vaccines that treat and provide protection against tumor growth. | 02-04-2016 |
20160030557 | Vaccines Having an Antigen and Interleukin-23 As An Adjuvant - Disclosed herein is a vaccine comprising an antigen and IL-23. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof. | 02-04-2016 |
20160038584 | Influenza Nucleic Acid Molecules And Vaccines Made Therefrom - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin and/or influenza B hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza A serotypes and/or influenza B serotypes, or combinations thereof, using the vaccines that are provided. | 02-11-2016 |
20160039886 | Foot and Mouth Disease Virus (FMDV) Consensus Proteins, Coding Sequences Therefor and Vaccines Made Therefrom - Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV. | 02-11-2016 |
20160045589 | Foot and Mouth Disease Virus (FMDV) Consensus Proteins, Coding Sequences Therefor and Vaccines Made Therefrom - The present invention relates to synthetic, consensus foot-and-mouth disease virus (FMDV) immunogenic proteins and nucleic acid molecule encoding such proteins, to vaccines against FMDV, to methods for inducing immune responses against FMVD, to methods for distinguishing between individuals infected with FMDV versus those vaccinated against FMDV, and methods of prophylactically and/or therapeutically immunizing individuals against FMDV. | 02-18-2016 |